









Markets
/
Stocks
/
nasdaq-trvi
/

Trevi Therapeutics Inc

TRVI

8.540USD

+0.560+7.02%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.04BMarket Cap

LossP/E TTM



Trevi Therapeutics Inc

8.540

+0.560+7.02%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

183 / 507

Overall Ranking

329 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

19.583

Target Price

+146.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 64.35.

Undervalued

The company’s latest PE is -18.98, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 94.28M shares, increasing 5.92% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 5.32M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -18.98, which is -65.01% below the recent high of -6.64 and 45.36% above the recent low of -10.37.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 183/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Trevi Therapeutics Inc is 20.00, with a high of 27.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

19.583

Target Price

+145.41%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Trevi Therapeutics Inc

TRVI

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 7.26, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 9.62 and the support level at 6.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.25

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.032

Buy

RSI(14)

52.209

Neutral

STOCH(KDJ)(9,3,3)

38.884

Sell

ATR(14)

0.696

Low Volatility

CCI(14)

15.757

Neutral

Williams %R

64.883

Sell

TRIX(12,20)

0.605

Sell

StochRSI(14)

0.861

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

8.401

Buy

MA10

8.189

Buy

MA20

7.797

Buy

MA50

7.461

Buy

MA100

6.873

Buy

MA200

5.776

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 77.42%, representing a quarter-over-quarter increase of 0.89%. The largest institutional shareholder is The Vanguard, holding a total of 5.32M shares, representing 4.37% of shares outstanding, with 9.43% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

11.37M

Frazier Life Sciences Management, L.P.

10.26M

-3.80%

Rubric Capital Management LP

4.54M

+7.93%

BlackRock Institutional Trust Company, N.A.

4.55M

+30.17%

The Vanguard Group, Inc.

Star Investors

3.84M

+9.37%

Vivo Capital, LLC

3.49M

Woodline Partners LP

2.06M

-35.95%

Invus Public Equities Advisors, LLC

2.86M

-1.45%

Octagon Capital Advisors LP

3.32M

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 5.60, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.71. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.